Cardio Diagnostics Holdings, Inc. announced that its PrecisionCHD and Epi+Gen CHD tests received preliminary pricing determinations from the Centers for Medicare & Medicaid Services (CMS). This decision, made on a 'gapfill' basis, followed the Clinical Laboratory Fee Schedule (CLFS) Annual Public Meeting held on June 25, 2024, and was issued in August 2024.
This preliminary determination is a crucial step toward securing Medicare reimbursement, which will enable access to the company’s blood tests for Medicare patients. If finalized, this decision will be effective for claims with dates of service on or after January 1, 2025.
The 'gapfill' pricing allows Medicare contractors to determine pricing based on actual cost data from Cardio Diagnostics. Medicare contractors are expected to report preliminary gapfill pricing for calendar year 2025 by April 1, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.